PN 400 clinical trials
Also written PN 400.
How each study uses PN 400 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2007 | 4 |
| 2008 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses PN 400 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedPhase 3POZENNCT00664560Written as PN 400 (VIMOVO)How we know
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedPhase 3POZENNCT00665431Written as PN 400 (VIMOVO)How we know
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedPhase 3POZENNCT00527787Written as PN400 (VIMOVO)How we know
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedPhase 3POZENNCT01129011Written as PN400 (VIMOVO)How we know
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to ArthrotecTerminatedPhase 3POZENNCT00594854Written as PN400 (VIMOVO)How we know
- A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)CompletedPhase 3POZENNCT00527904Written as PN400 (VIMOVO)How we know
- A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma LevelsCompletedPhase 1POZENNCT00749385Written as PN 400How we know